Status: Not yet recruiting
Gut Microbiome in DLBCL Treated With Glofitamab
The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.
Participants needed: 30
Trial details
Biological sex: AllType: ObservationalSponsor: Peking Union Medical College HospitalUpdated: Mar 27, 2026
Eligibility criteria
Histologically/cytologically confirmed diagnosis of DLBCL [+2]
Evidence of significant, uncontrolled concomitant diseases that could affect com... [+1]